Copyright
©The Author(s) 2021.
World J Gastroenterol. Aug 7, 2021; 27(29): 4913-4928
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4913
Published online Aug 7, 2021. doi: 10.3748/wjg.v27.i29.4913
Variable | SE | OR (95%CI) | Sensitivity | Specificity | Accuracy |
Crude model | 0.47 | 2.64 (1.04-6.92) | 0.62 | 0.61 | 0.61 |
Model 1 | 0.52 | 3.38 (1.24-9.98) | 0.60 | 0.73 | 0.64 |
Model 2 | 0.55 | 3.34 (1.17-10.40) | 0.71 | 0.68 | 0.69 |
Model 3 | 0.61 | 4.52 (1.44-16.28) | 0.78 | 0.72 | 0.75 |
Model 4 | 0.62 | 4.66 (1.45-17.16) | 0.77 | 0.77 | 0.77 |
- Citation: Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928
- URL: https://www.wjgnet.com/1007-9327/full/v27/i29/4913.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i29.4913